GEN Exclusives

More »

GEN News Highlights

More »
Mar 7, 2011

Bristol-Myers Squibb Taps WuXi for Stability Testing

  • WuXi PharmaTech will conduct stability studies of small molecule NCEs for Bristol-Myers Squibb to support global marketing applications. Under the agreement WuXi will build, equip, and operate a dedicated, fully cGMP-compliant 25,000 square foot analytical testing facility in Shanghai.

    It will store and test stability samples and perform other services for BMS at this site. WuXi will also employ a dedicated staff for stability testing, sample management, analytical testing, pharmaceutical science, quality assurance, metrology, and other services including stability data reporting in support of all global dossier submissions by Bristol-Myers Squibb.

    “WuXi PharmaTech is an important partner for Bristol-Myers Squibb’s research and development organization,” notes Mark Powell, Ph.D., senior vice president, nonclinical development, Bristol-Myers Squibb. “This agreement will expand the scope of our relationship with WuXi and enhance the presence of Bristol-Myers Squibb in China.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Tackling Climate Change

Do you think most companies will respond positively to the People’s Climate March?